prokidney.com (PROK) - Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan

The absence of commercial revenue and ongoing R&D expenditures define the current financial profile of ProKidney Corp. (PROK). The quarterly EPS trend reflects this trajectory, with -20.40 recorded as the baseline value. A high-tech cellular ecosystem with a closed-loop REACT tissue production cycle tightly integrates clinics with the company's logistics. The strategy focuses on safety validation and the completion of key trials for US regulators.

ProKidney Corp (PROK) - Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan saka 28.04.2023 nganti 13.11.2026

Rincian analitis perusahaan ProKidney Pharma (PROK)

- rega saham lan prakiraan rega para ahli:

Rega saham ProKidney|PROK - Prakiraan gabungan firma investasi

- indikator kapitalisasi pasar:

Nilai pasar ProKidney Inc.|PROK - Nilai Bisnis

- data kapitalisasi buku:

Nilai Buku saben Saham ProKidney|PROK - Ekuitas Perusahaan|Rasio Kapitalisasi marang Aset Bersih prokidney.com|PROK - Aset Perusahaan

- informasi babagan utang lan solvabilitas:

- indikator bathi lan kelipatan valuasi:

PROK - Asil keuangan resik|Proyeksi bathi mangsa ngarep ProKidney Corp.|PROK - Pangali rega marang bathi|Rega marang bathi mangsa ngarep ProKidney Inc.|PROK - Rasio P/E diaturake wutah|Pangali EV/EBITDA ProKidney Inc.|PROK - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan ProKidney|PROK - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan prokidney.com|PROK - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep ProKidney Corp.

- indikator volume dodolan lan pendapatan:

PROK - Dodolan perusahaan|Prakiraan pendapatan perusahaan ProKidney|PROK - Rega marang dodolan|Rasio rega marang prakiraan pendapatan ProKidney Inc.

Ringkesan analitik perusahaan:ProKidney Corp.

This indicator measures the quarterly dynamics of earnings per share (EPS). It allows for an assessment of the actual capital growth rate and the business's sensitivity to market fluctuations. By analyzing the quarterly EPS growth chart, an investor can determine the efficiency of resource management. For ProKidney Corp. (PROK), such data reflects the cost of intensive R&D for the REACT platform. Negative values here are expected when scaling breakthrough cellular technologies.

Analisis perusahaan pesaing